Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + recombinant human interferon α1b
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Cadonilimab + recombinant human interferon α1b is a combination therapy being investigated for the treatment of advanced melanoma. Cadonilimab is a first-in-class PD-1/CTLA-4 bispecific antibody that simultaneously blocks both the programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathways, enhancing anti-tumor immune responses. Recombinant human interferon α1b (IFN-α1b) is a cytokine that exhibits antiviral, antiproliferative, and immunomodulatory activities. The combination aims to leverage the synergistic effects of dual checkpoint inhibition and cytokine-mediated immune activation to improve outcomes in patients with Stage III/IV melanoma, particularly in the neoadjuvant setting.
- Brand names
- Kaitanni
- Other names
- AK104 + IFN-α1bCadonilimab + IFN-α1b
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on cadonilimab + recombinant human interferon α1b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + recombinant human interferon α1b.